Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also showed improvement in quality of life and daily functioning Additional findings from the PUNCH clinical trial program were presented, including the largest integrated safety analysis and data showing treatment with REBYOTA resulted […]

Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand for ADSTILADRIN Milestone prompts final $200 million payment from Royalty Pharma Parsippany, NJ – April 24, 2025 – Ferring Pharmaceuticals announced today […]

First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ADSTILADRIN as the new standard of care and backbone therapy for non-muscle invasive bladder cancer (NMIBC)1  Results showed 75% complete response rate at three months in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC patients receiving ADSTILADRIN (n=20) and is in addition to the […]